No Data
No Data
Wanbang Medicine (301520.SZ) will distribute 5 yuan for every 10 shares in 2023. The equity registration day is June 20th.
Wanbang Pharmaceutical (301520.SZ) announced that the company will implement the annual equity distribution for 2023, with 10 shares per...
Express News | CRO sector rebounds shock, Wanbang Pharmaceutical rises more than 15%.
Medical related stocks in A-shares have risen, with CRO direction leading the way.
On June 12th, Hua Hong Pharmaceutical rose more than 10%, previously reached limit up by Lionco Pharmaceutical Group, Hisoar Pharmaceutical, Jiangxi Synergy Pharmaceutical, Haoyuan Medicine, Pharmaron, Guangxi Hechi Chemical, Haoyuan Medicine, Jiangxi Fushine Pharmaceutical, Sailong Pharmaceutical Group, and WuXi AppTec were among the top gainers.
Wanbang Pharmaceutical (301520.SZ): has developed a sample analysis method for Semaglutide.
On June 5th, Gelon Hui reported that Wanbang Pharma (301520.SZ) has developed a sample analysis method for Simcereglutide, which is one of the clinical research links. At present, there are no related orders.
Wanbang Pharmaceutical (301520.SZ): The company has not yet carried out drug research and development work for the KP.2 variant
Gelonghui, May 20 | Wanbang Pharmaceutical (301520.SZ) said on the investor interactive platform that the company has not yet carried out drug research and development work on the KP.2 variant.
CRO concept stocks opened and surged. Baihua Pharmaceuticals rose and stopped. Wanbang Pharmaceuticals rose more than 17%, Pharmaceutical Kangde rose more than 8%, and Kanglong Chemical, Gloria Ying, and Tiger Pharmaceuticals all opened higher.
CRO concept stocks opened and surged. Baihua Pharmaceuticals rose and stopped. Wanbang Pharmaceuticals rose more than 17%, Pharmaceutical Kangde rose more than 8%, and Kanglong Chemical, Gloria Ying, and Tiger Pharmaceuticals all opened higher.
No Data